Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results

Turn Therapeutics (NASDAQ:TTRX) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share for the quarter, Zacks reports.

Turn Therapeutics Stock Down 2.5%

Turn Therapeutics stock opened at $3.12 on Thursday. The company has a market cap of $91.85 million and a price-to-earnings ratio of -44.57. The business’s 50 day moving average price is $3.68. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Weiss Ratings started coverage on shares of Turn Therapeutics in a research report on Monday, January 5th. They set a “sell (e-)” rating for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On Turn Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TTRX. Hodges Capital Management Inc. acquired a new position in shares of Turn Therapeutics in the 4th quarter valued at $39,000. LPL Financial LLC acquired a new stake in Turn Therapeutics during the 4th quarter worth $51,000. Jane Street Group LLC bought a new position in Turn Therapeutics during the fourth quarter worth about $68,000. Geode Capital Management LLC acquired a new position in Turn Therapeutics in the fourth quarter valued at about $68,000. Finally, HighTower Advisors LLC bought a new stake in shares of Turn Therapeutics in the fourth quarter worth about $78,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.